|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
Researcher makes his mark By establishing goals, Robert Ruffolo helped Wyeth step up its R&D game
This is a short, but very interesting, interview with Robert Ruffolo, head of research at Wyeth Pharmaceuticals. Ruffolo discusses Wyeth's metric driven research strategy and why the risks of drugs have to be measured against their benefits.
Every drug should be prescribed based on its risk and its benefit. It's a ratio. What frustrates me right now is the almost obsessive focus on risk is only one part of that ratio. Did you ever take your calculator and put in a number and divide it by zero. Do you know what it will tell you? Does not compute. You can't divide by zero. When I see and read debates about risk, risk, risk, it doesn't mean anything unless you put it in context with the benefit.
|home spotlight commentary research events news about contact links archives|